Research programme: leucocyte elastase inhibitors - Dainippon Sumitomo Pharma

Drug Profile

Research programme: leucocyte elastase inhibitors - Dainippon Sumitomo Pharma

Alternative Names: BL-3879; BL-5160; HNE inhibitors research programme - Dainippon Pharmaceutical; Human neutrophil elastase inhibitors research programme - Dainippon Pharmaceutical; Leucocyte elastase inhibitors research programme - Dainippon Pharmaceutical; Research programme: HNE inhibitors - Dainippon Pharmaceutical; Research programme: human neutrophil elastase inhibitors - Dainippon Pharmaceutical

Latest Information Update: 08 Feb 2008

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Dainippon Sumitomo Pharma
  • Class
  • Mechanism of Action Leucocyte elastase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Chronic obstructive pulmonary disease

Most Recent Events

  • 08 Feb 2008 Discontinued - Preclinical for Chronic obstructive pulmonary disease in Japan (PO)
  • 01 Oct 2005 Sumitomo Pharmaceuticals has merged with Dainippon Pharmaceutical to form Dainippon Sumitomo Pharma
  • 23 Sep 2005 Preclinical trials in Chronic obstructive pulmonary disease in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top